Equities Analysts Set Expectations for Nemaura Medical Inc.’s Q3 2023 Earnings (NASDAQ:NMRD)

Nemaura Medical Inc. (NASDAQ:NMRDGet Rating) – HC Wainwright decreased their Q3 2023 earnings per share estimates for Nemaura Medical in a report released on Monday, November 21st. HC Wainwright analyst Y. Chen now expects that the company will post earnings of ($0.18) per share for the quarter, down from their previous estimate of ($0.16). HC Wainwright currently has a “Buy” rating and a $8.00 price target on the stock. The consensus estimate for Nemaura Medical’s current full-year earnings is ($0.64) per share. HC Wainwright also issued estimates for Nemaura Medical’s Q4 2023 earnings at ($0.17) EPS, FY2023 earnings at ($0.69) EPS, Q1 2024 earnings at ($0.15) EPS, Q2 2024 earnings at ($0.14) EPS, Q3 2024 earnings at ($0.13) EPS, Q4 2024 earnings at ($0.12) EPS and FY2024 earnings at ($0.55) EPS.

Nemaura Medical Stock Performance

NASDAQ:NMRD opened at $2.00 on Thursday. Nemaura Medical has a twelve month low of $1.50 and a twelve month high of $5.94. The company has a market cap of $48.20 million, a P/E ratio of -3.13 and a beta of 0.01. The company’s 50-day moving average price is $2.19 and its 200-day moving average price is $2.29.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Nemaura Medical stock. ARS Investment Partners LLC boosted its holdings in Nemaura Medical Inc. (NASDAQ:NMRDGet Rating) by 12.8% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 86,876 shares of the company’s stock after acquiring an additional 9,849 shares during the period. ARS Investment Partners LLC owned 0.36% of Nemaura Medical worth $223,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 3.47% of the company’s stock.

About Nemaura Medical

(Get Rating)

Nemaura Medical Inc, a medical technology company, discovers, develops, and commercializes diagnostic medical devices. It provides sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and reversal programs.

Recommended Stories

Receive News & Ratings for Nemaura Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nemaura Medical and related companies with MarketBeat.com's FREE daily email newsletter.